Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis

Lachaine, J.; Hodge, William; Steffensen, I; Murray, Christine; Barnes, David; Foerster, Vicki; Ducruet, Thiérry; Mensinkai, Shaila

doi:10.3129/i07-182

Cited by 16 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, a newer study done in Canada suggested that for patients in whom timolol is not contraindicated, it would be preferable, from a cost-effectiveness standpoint, to initiate treatment with timolol and reserve the prostaglandin analogues as an alternative treatment or as add-on therapy for patients not achieving a clinical response with timolol. The reasons being, although latanoprost is arguably more effective in its IOP-lowering effects than dorzolamide, brimonidine, or timolol, it is also more expensive (Lachaine et al 2008). However, these studies are at best conflicting in their findings.…”

Section: Socioeconomic Burdenmentioning

confidence: 99%

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

Kulkarni¹,

Damji²,

Buys³

2008

PPA

View full text Add to dashboard Cite

Primary open angle glaucoma is a chronic optic neuropathy often requiring lifelong treatment. Patient compliance, adherence and persistence with therapy play a vital role in improved outcomes by reducing morbidity and the economic consequences that are associated with disease progression. A literature review including searches of The Cochrane Library, MEDLINE, PubMed, conference proceedings, and bibliographies of identified articles reveals the enormous public health burden in various populations due to the impact of glaucoma associated visual impairment on the overall quality of life eg, fear of blindness, inability to work in certain occupations, driving restrictions, motor vehicle accidents, falls, and general health status. Providing specific definitions for the frequently misunderstood terms “compliance, persistence and adherence” with reference to medication use is central not only for monitoring patients’ drug dosing histories and clinical outcomes but also for subsequent research. In this review article, a summary of the advantages/disadvantages including cost-effectiveness of various medical approaches to glaucoma treatment, techniques employed for measuring patient compliance and actual patient preferences for therapy are outlined. We conclude by identifying the key barriers to ongoing treatment and suggest some best practices to enhance compliance and persistence.

show abstract

Section: Socioeconomic Burdenmentioning

confidence: 99%

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

Kulkarni¹,

Damji²,

Buys³

2008

PPA

View full text Add to dashboard Cite

show abstract

“…The topical medication cost was calculated following methods used in previously published reports. [15][16][17][18] The cost of each bottle of medication was determined using the amounts reimbursed by the Ontario Drug Benefit Formulary. 19 All values are reported as Canadian dollars.…”

Section: Methodsmentioning

confidence: 99%

Economic Analysis of the Ex-PRESS Miniature Glaucoma Device Versus Trabeculectomy

Patel

Wagschal

Trope

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Lachaine et al (2008) used IOP reduction in millimeters of mercury (compared with baseline and the incidence of adverse events) as the effectiveness data of the most used glaucoma medications, and found that dorzolamide, compared with latanoprost, is not a cost-effective strategy. Latanoprost, compared with brimonidine, has provided a higher IOP reduction with an incremental cost-effectiveness ratio, but the additional IOP reduction with latanoprost was obtained at a higher cost than the average cost per millimeter of mercury reduction obtained with brimonidine.…”

Section: Latanoprost Ophthalmic Solutionmentioning

confidence: 99%

“…Latanoprost, compared with brimonidine, has provided a higher IOP reduction with an incremental cost-effectiveness ratio, but the additional IOP reduction with latanoprost was obtained at a higher cost than the average cost per millimeter of mercury reduction obtained with brimonidine. Compared with timolol, latanoprost had a positive incremental cost-effectiveness ratio (Lachaine et al 2008). Payet et al (2008) assessed the cost-effectiveness of latanoprost versus travoprost as single agents for the treatment of glaucoma in France and pointed out that travoprost demonstrated a longer effectiveness profi le than latanoprost, although travoprost was more expensive than latanoprost (additional 5-year costs for travoprost were €51).…”

Section: Latanoprost Ophthalmic Solutionmentioning

confidence: 99%

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Quaranta¹

2009

OPTH

View full text Add to dashboard Cite

Latanoprost is a prostaglandin F2-alpha isopropyl ester prodrug which is rapidly hydrolyzed by esterases in the cornea to the biologically active latanoprost acid. When latanoprost is topically administered into the eye, the cornea seems to act like as a slow-release depot to the anterior segment. One hour after administration maximum concentration is found in the iris, followed by the anterior chamber and the ciliary body. Despite extensive research, controversy remains about the real mechanism of action of this drug. Immunohistochemical data have shown that the intraocular pressure (IOP) reduction with topical prostaglandin F2-alpha is associated with a reduction of collagens within the uveoscleral outfl ow pathway. Evidence from several experimental and clinical studies suggests that latanoprost is a valuable addition fi rst-line treatment alternatives for glaucoma, ocular hypertension and even angle-closure glaucoma. Strong points are its effi cacy, which is demonstrated to be higher than that of brimonidine, dorzolamide and timolol with fewer systemic adverse effects; a convenient administration schedule; and the IOP-controlling pattern, which is relatively fl at compared with timolol and dorzolamide, and enables better control in glaucoma progression, since large fl uctuations may be associated with the risk of developing glaucoma in untreated ocular hypertensive subjects.

show abstract

Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis

Cited by 16 publications

References 43 publications

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

Economic Analysis of the Ex-PRESS Miniature Glaucoma Device Versus Trabeculectomy

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Contact Info

Product

Resources

About